DE60332562D1 - Therapeutische Piperazinverbindungen - Google Patents

Therapeutische Piperazinverbindungen

Info

Publication number
DE60332562D1
DE60332562D1 DE60332562T DE60332562T DE60332562D1 DE 60332562 D1 DE60332562 D1 DE 60332562D1 DE 60332562 T DE60332562 T DE 60332562T DE 60332562 T DE60332562 T DE 60332562T DE 60332562 D1 DE60332562 D1 DE 60332562D1
Authority
DE
Germany
Prior art keywords
piperazine compounds
therapeutic
therapeutic piperazine
compounds
hydroxyiminopiperzine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60332562T
Other languages
English (en)
Inventor
Qun Sun
Xiaoming Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Application granted granted Critical
Publication of DE60332562D1 publication Critical patent/DE60332562D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
DE60332562T 2002-09-24 2003-09-24 Therapeutische Piperazinverbindungen Expired - Lifetime DE60332562D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41284702P 2002-09-24 2002-09-24

Publications (1)

Publication Number Publication Date
DE60332562D1 true DE60332562D1 (de) 2010-06-24

Family

ID=32043195

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60312544T Expired - Lifetime DE60312544T2 (de) 2002-09-24 2003-09-24 Therapeutische piperazin verbindungen.
DE60332562T Expired - Lifetime DE60332562D1 (de) 2002-09-24 2003-09-24 Therapeutische Piperazinverbindungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60312544T Expired - Lifetime DE60312544T2 (de) 2002-09-24 2003-09-24 Therapeutische piperazin verbindungen.

Country Status (20)

Country Link
US (4) US7157462B2 (de)
EP (2) EP1562936B1 (de)
JP (1) JP4560610B2 (de)
KR (1) KR20050052514A (de)
CN (1) CN100393713C (de)
AT (2) ATE467627T1 (de)
AU (1) AU2003272685A1 (de)
BR (1) BR0314699A (de)
CA (1) CA2500113C (de)
CY (1) CY1106634T1 (de)
DE (2) DE60312544T2 (de)
DK (1) DK1562936T3 (de)
ES (1) ES2285170T3 (de)
HK (1) HK1083216A1 (de)
MX (1) MXPA05003302A (de)
NZ (1) NZ539205A (de)
PT (1) PT1562936E (de)
SI (1) SI1562936T1 (de)
WO (1) WO2004029031A2 (de)
ZA (1) ZA200502326B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100891887B1 (ko) 2001-01-29 2009-04-03 시오노기세이야쿠가부시키가이샤 5-메틸-1-페닐-2-(1ｈ)-피리돈을 활성 성분으로서 함유하는의약 제제
US7157462B2 (en) * 2002-09-24 2007-01-02 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US7582635B2 (en) 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
KR100896499B1 (ko) 2003-07-24 2009-05-08 유로-셀띠끄 소시에떼 아노님 통증 치료 또는 예방에 유용한헤테로아릴-테트라하이드로피페리딜 화합물
GEP20094676B (en) * 2003-07-24 2009-05-10 Euro Celtique Sa Piperidine compounds and pharmaceutical compositions containing them
SI1648880T1 (sl) * 2003-08-01 2010-05-31 Euro Celtique Sa Terapevtska sredstva uporabna za zdravljenje bolečine
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
EA026785B1 (ru) 2005-05-10 2017-05-31 Инсайт Холдингс Корпорейшн Модуляторы индоламин 2,3-диоксигеназы и способы их применения
ES2540561T3 (es) 2005-12-20 2015-07-10 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
US20070203140A1 (en) * 2006-02-09 2007-08-30 Combs Andrew P N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
MX2008013441A (es) * 2006-04-19 2009-02-11 Jill P Smith Tratamiento de enfermedades inflamatorias y ulcerativas del intestino con antagonistas opioides.
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
US20080125470A1 (en) 2006-09-19 2008-05-29 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
WO2008057300A2 (en) * 2006-10-27 2008-05-15 Redpoint Bio Corporation Trpvi antagonists and uses thereof
AR066146A1 (es) 2007-04-27 2009-07-29 Shionogi & Co Antagonistas de trpvi y usos de los mismos
WO2009052377A1 (en) * 2007-10-18 2009-04-23 Harry Fisch Treatment of migraine headaches using antiestrogens
EP2238105B1 (de) 2008-01-28 2014-04-16 Amorepacific Corporation Neuartige verbindungen, isomer daraus oder pharmazeutisch akzeptable salze davon als vanilloid-rezeptorantagonisten sowie pharmazeutische zusammensetzungen damit
JP5438103B2 (ja) 2008-07-02 2014-03-12 アモーレパシフィック コーポレイション バニロイド受容体アンタゴニストとしての新規化合物、その異性体またはその薬学的に許容される塩、並びにそれを含む医薬組成物
DK2824100T3 (en) 2008-07-08 2018-04-16 Incyte Holdings Corp 1,2,5-oxadiazoles as inhibitors of indolamine-2,3-dioxygenase
WO2011103091A1 (en) 2010-02-18 2011-08-25 Transtech Pharma, Inc. Phenyl-heteroaryl derivatives and methods of use thereof
JP5876423B2 (ja) 2010-06-22 2016-03-02 塩野義製薬株式会社 Ｔｒｐｖ１阻害活性を有する化合物とその使用
EP2709609B1 (de) 2011-05-17 2017-10-04 Shionogi & Co., Ltd. Heterozyklische verbindungen
AU2012273652B2 (en) 2011-06-22 2015-09-03 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
BR122020009912B1 (pt) 2013-11-08 2022-11-01 Incyte Holdings Corporation Processo para a síntese de um inibidor de indoleamina 2,3-dioxigenase
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
EP3586309B1 (de) 2017-02-24 2023-04-05 Brainlab AG Einstellung für anhalten des atems bei tiefem einatmen mittels röntgenbildgebung
AU2022267044A1 (en) 2021-04-26 2023-11-30 Pathios Therapeutics Limited Compounds
DE102022104759A1 (de) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450272A (en) 1982-05-06 1984-05-22 American Cyanamid Company Antiatherosclerotic 1-piperazine-thicarboxamides
US4439606A (en) 1982-05-06 1984-03-27 American Cyanamid Company Antiatherosclerotic 1-piperazinecarbonyl compounds
US5316759A (en) 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
US5198459A (en) 1987-07-11 1993-03-30 Sandoz Ltd. Use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents
DE3822792C2 (de) 1987-07-11 1997-11-27 Sandoz Ag Neue Verwendung von 5HT¶3¶-Antagonisten
US5075341A (en) 1989-12-01 1991-12-24 The Mclean Hospital Corporation Treatment for cocaine abuse
US6204284B1 (en) 1991-12-20 2001-03-20 American Cyanamid Company Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies
US5232934A (en) 1992-07-17 1993-08-03 Warner-Lambert Co. Method for the treatment of psychomotor stimulant addiction
DE4234295A1 (de) 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5321012A (en) 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
GB9306578D0 (en) 1993-03-30 1993-05-26 Merck Sharp & Dohme Therapeutic agents
GB9308725D0 (en) 1993-04-27 1993-06-09 Wyeth John & Brother Ltd Piperazine derivatives
US5461047A (en) 1993-06-16 1995-10-24 G. D. Searle & Co. 2-,3-,4-,5-,6-,7-,8-,9- and/or 10-substituted dibenzoxazepine and dibenzthiazepine compounds, pharmaceutical compositions and methods of use
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
FR2722788B1 (fr) 1994-07-20 1996-10-04 Pf Medicament Nouvelles piperazides derivees d'aryl piperazine, leurs procedes de preparation, leur utilisation a titre de medicament et les compositions pharmaceutiques les comprenant
US5556837A (en) 1994-08-01 1996-09-17 Regeneron Pharmaceuticals Inc. Methods for treating addictive disorders
US5762925A (en) 1994-11-03 1998-06-09 Sagen; Jacqueline Preventing opiate tolerance by cellular implantation
WO1996021648A1 (en) 1995-01-11 1996-07-18 Samjin Pharmaceutical Co., Ltd. New piperazine derivatives and methods for the preparation thereof and compositions containing the same
RU2146254C1 (ru) 1996-06-29 2000-03-10 Самдзин Фармасьютикал Ко., Лтд. Производные пиперазина и способ их получения
JP2003524574A (ja) 1997-08-05 2003-08-19 ノボ ノルディスク アクティーゼルスカブ ２，５−及び３，５−二置換アニリン誘導体、その調製及び使用
CA2326324C (en) 1998-03-31 2010-05-11 Kyowa Hakko Kogyo Co., Ltd. Nitrogen-containing heterocyclic compound
US6329395B1 (en) 1998-06-08 2001-12-11 Schering Corporation Neuropeptide Y5 receptor antagonists
ATE384048T1 (de) 1998-09-22 2008-02-15 Astellas Pharma Inc Cyanophenyl-derivate
EP1424072A1 (de) * 1999-03-03 2004-06-02 Samjin Pharmaceutical Co., Ltd. N'-(Pyridin-3-yl)-(4-Phenylpiperazin-1-yl)-Carboxyimidamid und -Iminothiolat Derivate zur Behandlung vom Tumoren
US6109269A (en) 1999-04-30 2000-08-29 Medtronic, Inc. Method of treating addiction by brain infusion
EP1313477A4 (de) 2000-07-15 2004-03-03 Smithkline Beecham Corp Zusammenstellungen und methoden
WO2002008221A2 (en) * 2000-07-20 2002-01-31 Neurogen Corporation Capsaicin receptor ligands
CN100439332C (zh) 2000-08-21 2008-12-03 株式会社太平洋 硫脲衍生物以及包含该衍生物的药物组合物
KR100453078B1 (ko) 2000-08-21 2004-10-15 주식회사 태평양 신규 티오우레아 화합물 및 이를 함유하는 약제학적 조성물
TWI283665B (en) 2001-09-13 2007-07-11 Smithkline Beecham Plc Novel urea compound, pharmaceutical composition containing the same and its use
KR20040085151A (ko) 2002-01-17 2004-10-07 뉴로젠 코포레이션 캡사이신 조절자로서의 치환된 퀴나졸린-4-일 아민 유사체
AR038420A1 (es) 2002-02-15 2005-01-12 Glaxo Group Ltd Compuesto de amida, procedimiento para la preparacion del mismo, su uso para la fabricacion de un medicamento y composicion farmaceutica que lo comprende
US7074805B2 (en) 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US20030158188A1 (en) 2002-02-20 2003-08-21 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
EP1556354B1 (de) 2002-06-28 2008-01-23 Euro-Celtique S.A. Therapeutische piperazin-derivate für die behandlung von schmerzen
US7157462B2 (en) 2002-09-24 2007-01-02 Euro-Celtique S.A. Therapeutic agents useful for treating pain
GEP20094676B (en) 2003-07-24 2009-05-10 Euro Celtique Sa Piperidine compounds and pharmaceutical compositions containing them
KR100896499B1 (ko) 2003-07-24 2009-05-08 유로-셀띠끄 소시에떼 아노님 통증 치료 또는 예방에 유용한헤테로아릴-테트라하이드로피페리딜 화합물
DK1727801T3 (da) 2003-12-30 2009-05-11 Euro Celtique Sa Til behandling af smerter anvendelige piperaziner

Also Published As

Publication number Publication date
JP2006508067A (ja) 2006-03-09
US20050059671A1 (en) 2005-03-17
WO2004029031A2 (en) 2004-04-08
ES2285170T3 (es) 2007-11-16
EP1810970B1 (de) 2010-05-12
CN100393713C (zh) 2008-06-11
US20070142360A1 (en) 2007-06-21
KR20050052514A (ko) 2005-06-02
HK1083216A1 (en) 2006-06-30
PT1562936E (pt) 2007-06-12
ZA200502326B (en) 2006-05-31
EP1562936A2 (de) 2005-08-17
DE60312544D1 (de) 2007-04-26
DK1562936T3 (da) 2007-07-16
SI1562936T1 (sl) 2007-08-31
EP1810970B8 (de) 2012-03-21
US20090042902A1 (en) 2009-02-12
CA2500113C (en) 2011-07-12
US20110082152A1 (en) 2011-04-07
AU2003272685A1 (en) 2004-04-19
US7855210B2 (en) 2010-12-21
WO2004029031A3 (en) 2004-08-05
NZ539205A (en) 2007-05-31
EP1562936B1 (de) 2007-03-14
ATE356817T1 (de) 2007-04-15
US7737148B2 (en) 2010-06-15
EP1810970A1 (de) 2007-07-25
US7157462B2 (en) 2007-01-02
BR0314699A (pt) 2005-08-09
ATE467627T1 (de) 2010-05-15
CA2500113A1 (en) 2004-04-08
DE60312544T2 (de) 2007-12-13
MXPA05003302A (es) 2005-10-18
JP4560610B2 (ja) 2010-10-13
CN1701071A (zh) 2005-11-23
CY1106634T1 (el) 2012-01-25

Similar Documents

Publication Publication Date Title
DE60332562D1 (de) Therapeutische Piperazinverbindungen
NO20063275L (no) Anvendelse av substituerte 2-aminotetraliner for forebyggende behandling av Parkinsons sykdom
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
GB0325956D0 (en) Novel compounds
SI1392642T1 (sl) Nove spojine kot protivnetna, imunomodulacijska in antiproliferativna sredstva
ATE453393T1 (de) Verwendung von pyridylamiden als angiogenesehemmer
NO20032801L (no) Tiazolderivater for behandling av PPAR-relaterte forstyrrelser
TW200510405A (en) Bridged n-arylsulfonylpiperidines as gamma-secretase inhibitors
HK1107700A1 (en) Triazole compounds that modulate hsp90 activity
DE602004029242D1 (en) Pyrazolamidverbindungen
IL175398A0 (en) Steroidal compounds and pharmaceutical compositions containing them for treating oxidative stress and inflammation
PL1663185T3 (pl) Zapobieganie i leczenie utraty kości wywołanej przez zapalenie i/lub za pośrednictwem układu odpornościowego
HK1094191A1 (en) Phenyl-carboxamide compounds useful for treating pain
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
ATE410203T1 (de) Lipase-hemmende zusammensetzung
DE60218837D1 (de) Verbindungen und verfahren zur hemmung des achselgeruches
MY138466A (en) Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders
ATE380816T1 (de) Substituierte imidazopyrimidine zur prävention und behandlung von krebs
DK1197223T3 (da) Farmaceutisk præparat til forebyggelse, behandling eller udviklingsinhibition af simpel retinopati eller præproliferativ retinopati
NO20032411D0 (no) Anvendelse av substituerte 6-dimetylaminometyl-1-fenyl- cykloheksan-forbindelser for behandling av urininkontinens
ATE276259T1 (de) Dihydroporphyrinderivate und ihre verwendung
BR0307266A (pt) Compostos que inibem a atividade do fator xa
DK1312608T3 (da) Discodermolid-analoge samt deres farmaceutiske anvendelse
MXPA04006600A (es) Dihidrotiazina-y dihidrotiopiran-oxazolidinonas antimicrobianas.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition